Proactive Investors - Run By Investors For Investors

Indivior falls again as US court ruling clears way for launch of Suboxone generic

Suboxone is Indivor’s big money-maker, but two generic versions could hit the market as early as next Tuesday after the latest ruling from a US appeals court
suboxone
Indivior is adamant that the generics infringe on its patents and is taking its case to the Supreme Court

Indivior PLC (LON:INDV) has been dealt another blow in its bid to protect its star drug after a US court ruling cleared the way for two rivals to launch their generic versions of the opioid addiction next week.

The drugmaker has been aggressively defending Suboxone, which makes up the bulk of its annual revenue, for several years now, claiming that cut-price treatments from Dr Reddy’s and Alvogen infringe on its patents.

READ: Federal court rejects Suboxone appeal

But last week, a US appeals court ratified an earlier decision by a district court in Delaware that gave the generics the all-clear.

Indivior is taking its case to the Supreme Court, the highest court in the US, and had hoped to delay the launch of the copycat versions until after then.

But that request has been rejected by the appeals court, which has told Indian giant Dr Reddy’s and Alvogen that they can start selling their drugs into the market next Tuesday (19 February).

Dr Reddy’s not averse to an ‘at-risk’ launch

Any launch would be on an ‘at-risk’ basis though – when litigation is still going – as Indivior is still trying to protect its intellectual property (IP) through a court in New Jersey as well as the Supreme Court.

That wasn’t a concern for Dr Reddy’s last summer though when it briefly launched its version ‘at-risk’ and took a decent chunk out of Suboxone’s market share despite only being available for a few hours.

Indivior shares were down 2.2% to 104.7p. Last summer they were changing hands for more than 500p.

View full INDV profile View Profile

Indivior Timeline

Related Articles

Social media use
April 19 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
Sativa
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use